These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9378077)

  • 1. Pharmacology of ribosomal immunotherapy.
    Clot J
    Drugs; 1997; 54 Suppl 1():33-6. PubMed ID: 9378077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Streptococcus pneumoniae adhesion by specific salivary IgA after oral immunisation with a ribosomal immunostimulant.
    Hbabi-Haddioui L; Roques C
    Drugs; 1997; 54 Suppl 1():29-32. PubMed ID: 9378076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunostimulants revisited: focus on the pharmacology of Ribomunyl.
    Portalès P; Clot J
    BioDrugs; 2006; 20(2):81-4. PubMed ID: 16626165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From Peyer's patches to tonsils. Specific stimulation with ribosomal immunotherapy.
    Béné MC; Faure GC
    Drugs; 1997; 54 Suppl 1():24-8. PubMed ID: 9378075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delivery with polycations extends the immunostimulant Ribomunyl into a potent antiviral Toll-like receptor 7/8 agonist.
    Herberhold S; Coch C; Zillinger T; Hommertgen B; Busch N; Schuberth C; Hartmann E; Wimmenauer V; Hagmann CA; Lüdenbach B; Schlee M; Bootz F; Hartmann G; Barchet W
    Antivir Ther; 2011; 16(5):751-8. PubMed ID: 21817197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The immunostimulant RU41740 from Klebsiella pneumoniae activates human cells in whole blood to potentially stimulate innate and adaptive immune responses.
    Pedraza-Sánchez S; González-Hernández Y; Escobar-Gutiérrez A; Ramachandra L
    Int Immunopharmacol; 2006 Apr; 6(4):635-46. PubMed ID: 16504927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bacterial ribosomal immunostimulants prime alveolar macrophages in vivo to produce interleukin 1 in vitro.
    Pujol JL; Klein B; Godard P; Dussourd d'Hinterland L; Michel FB
    Chest; 1991 Sep; 100(3):644-8. PubMed ID: 1889248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of recurrent respiratory tract infections in children using a ribosomal immunotherapeutic agent: a clinical review.
    Bousquet J; Fiocchi A
    Paediatr Drugs; 2006; 8(4):235-43. PubMed ID: 16898854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ex vivo study of the effect of ribomunyl on the release of oxygen radicals by polynuclear neutrophils].
    Rahimy MC; Bernaudin F; Doppelt E; de la Rocque F; Plan D; Reinert PH; Bernaudin JF
    Allerg Immunol (Paris); 1989 May; 21(5):201-3. PubMed ID: 2736038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro stimulation of polymorphonuclear cell adhesion by ribomunyl and antibiotic + ribomunyl combinations: effects on CD18, CD35 and CD16 expression.
    Hbabi L; Roques C; Michel G; Perruchet AM; Benoist H
    Int J Immunopharmacol; 1993 Feb; 15(2):163-73. PubMed ID: 8096833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of ribosomal fractions of Klebsiella pneumoniae, Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae and the membrane fraction of Kp (Ribomunyl) in the prevention of clinical recurrences of infectious rhinitis. Results of a multicenter double-blind placebo-controlled study.
    Serrano E; Demanez JP; Morgon A; Chastang C; Van Cauwenberge P
    Eur Arch Otorhinolaryngol; 1997; 254(8):372-5. PubMed ID: 9332892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of ribomunyl((r)) in the prevention of recurrent respiratory tract infections in adults : overview of clinical results.
    Bousquet J; Oliveri D
    Treat Respir Med; 2006; 5(5):317-24. PubMed ID: 16928145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics of specific salivary IgA responses in man after oral challenge by ribosomal immunostimulant.
    Kolopp-Sarda MN; Béné ME; Allaire JM; Perruchet AM; Faure GC
    Int J Immunopharmacol; 1997 Mar; 19(3):181-6. PubMed ID: 9306157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific antibody-producing cells in humans after oral immunization with a ribosomal vaccine Ribomunyl.
    Bene MC; Zanin C; Perrin P; Perruchet AM; Molé CM; Faure GC
    Adv Exp Med Biol; 1995; 371B():1563-6. PubMed ID: 7502857
    [No Abstract]   [Full Text] [Related]  

  • 15. Rationale for the clinical use of a ribosome-component immune modulator.
    Pregliasco F; Terracciano L; Marcassa S; Zava D; Anselmi G
    Allergy Asthma Proc; 2009; 30 Suppl 1():S5-12. PubMed ID: 19679000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of IL-1 and TNF in the ribomunyl-induced radio-protection.
    Vávrová J
    Folia Biol (Praha); 1995; 41(1):23-30. PubMed ID: 7621966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a clinical-grade maturation factor for dendritic cells.
    Boccaccio C; Jacod S; Kaiser A; Boyer A; Abastado JP; Nardin A
    J Immunother; 2002; 25(1):88-96. PubMed ID: 11924914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclic di-GMP stimulates protective innate immunity in bacterial pneumonia.
    Karaolis DK; Newstead MW; Zeng X; Hyodo M; Hayakawa Y; Bhan U; Liang H; Standiford TJ
    Infect Immun; 2007 Oct; 75(10):4942-50. PubMed ID: 17646358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LPS-stimulated SJL macrophages produce IL-12 and IL-18 that inhibit IgE production in vitro by induction of IFN-gamma production from CD3intIL-2R beta+ T cells.
    Yoshimoto T; Nagai N; Ohkusu K; Ueda H; Okamura H; Nakanishi K
    J Immunol; 1998 Aug; 161(3):1483-92. PubMed ID: 9686615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Micro-Immunotherapy Medicine 2LEID Exhibits an Immunostimulant Effect by Boosting Both Innate and Adaptive Immune Responses.
    Jacques C; Chatelais M; Fekir K; Fauconnier L; Mellier M; Togbe D; Floris I
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.